Who is sponsoring NCT01150201?

NCT01150201 is sponsored by The University of Hong Kong.

What condition does NCT01150201 study?

NCT01150201 studies Kidney Disease.

What drugs are being tested in NCT01150201?

Interventions: Aliskiren, Losartan.

What is the status of NCT01150201?

NCT01150201 is currently COMPLETED.

Last reviewed 2015-07-02 · How we verify

Phase 4 Study of the Renoprotective Efficacy of Aliskiren in Addition to Angiotensin II Receptor Blocker in Chronic Kidney Disease

NCT01150201 Phase 4 COMPLETED

Study objective: To investigate the potential anti-proteinuric and renoprotective efficacy of aliskiren in addition to losartan in patients at risk of developing end-stage renal disease (ESRD) Methods: This will be a randomized, double-blind study in which proteinuric, non-diabetic patients with chronic kidney disease (CKD) will be assigned in a 1:1 ratio to one of the following treatment groups for 3 years: * Group A: Losartan (Control arm: conventional treatment)\* * Group B: Aliskiren plus Losartan (Intervention arm)\* * With optional addition of other anti-hypertensive agents to achieve an optimal target blood pressure of \<130/80 mmHg.

Details

Lead sponsor	The University of Hong Kong
Phase	Phase 4
Status	COMPLETED
Enrolment	80
Start date	2009-07
Completion	2014-08

Conditions

Kidney Disease

Interventions

Aliskiren
Losartan

Primary outcomes

Rate of change in GFR — 36 months

Countries

China